The ASCO Post
@ascopost.bsky.social
News and views from the world of clinical oncology and hematology
🚨 Cancer workforce shortages threaten patient access & research progress, according to a report from the President’s Cancer Panel.
🔹Report by Mitchel S. Berger, MD & Carol L. Brown, MD
Learn about recommendations for addressing shortages 👉 https://ow.ly/nEeA50Y5oX2
🔹Report by Mitchel S. Berger, MD & Carol L. Brown, MD
Learn about recommendations for addressing shortages 👉 https://ow.ly/nEeA50Y5oX2
January 29, 2026 at 6:30 PM
🚨 Cancer workforce shortages threaten patient access & research progress, according to a report from the President’s Cancer Panel.
🔹Report by Mitchel S. Berger, MD & Carol L. Brown, MD
Learn about recommendations for addressing shortages 👉 https://ow.ly/nEeA50Y5oX2
🔹Report by Mitchel S. Berger, MD & Carol L. Brown, MD
Learn about recommendations for addressing shortages 👉 https://ow.ly/nEeA50Y5oX2
🚨 New American Cancer Society study: States that limit/don’t allow short-term health plans saw delays in timely cancer treatment initiation after diagnosis. Health insurance is a major factor in survival. #CancerCare
✍️ Jingxuan Zhao, PhD
🔗 https://ow.ly/kPMk50Y4UpZ
✍️ Jingxuan Zhao, PhD
🔗 https://ow.ly/kPMk50Y4UpZ
January 28, 2026 at 7:30 PM
🚨 New American Cancer Society study: States that limit/don’t allow short-term health plans saw delays in timely cancer treatment initiation after diagnosis. Health insurance is a major factor in survival. #CancerCare
✍️ Jingxuan Zhao, PhD
🔗 https://ow.ly/kPMk50Y4UpZ
✍️ Jingxuan Zhao, PhD
🔗 https://ow.ly/kPMk50Y4UpZ
🧠 Targeted therapy shows activity in aggressive meningiomas.
In a phase II Alliance trial, abemaciclib slowed tumor growth in patients with NF2 mutations or CDK pathway–altered meningiomas.
Priscilla Brastianos, MD
🔗 https://ow.ly/4ZCp50Y3UoA
In a phase II Alliance trial, abemaciclib slowed tumor growth in patients with NF2 mutations or CDK pathway–altered meningiomas.
Priscilla Brastianos, MD
🔗 https://ow.ly/4ZCp50Y3UoA
January 27, 2026 at 1:00 PM
🧠 Targeted therapy shows activity in aggressive meningiomas.
In a phase II Alliance trial, abemaciclib slowed tumor growth in patients with NF2 mutations or CDK pathway–altered meningiomas.
Priscilla Brastianos, MD
🔗 https://ow.ly/4ZCp50Y3UoA
In a phase II Alliance trial, abemaciclib slowed tumor growth in patients with NF2 mutations or CDK pathway–altered meningiomas.
Priscilla Brastianos, MD
🔗 https://ow.ly/4ZCp50Y3UoA
🕊️ “A Battle With My Blood” - the final essay by Tatiana Celia Kennedy Schlossberg, recounting her diagnosis with aggressive acute myeloid leukemia and her search for meaning, hope, and memory.
https://ascopost.com/issues/january-25-2026/a-battle-with-my-blood/
https://ascopost.com/issues/january-25-2026/a-battle-with-my-blood/
January 26, 2026 at 6:15 PM
🕊️ “A Battle With My Blood” - the final essay by Tatiana Celia Kennedy Schlossberg, recounting her diagnosis with aggressive acute myeloid leukemia and her search for meaning, hope, and memory.
https://ascopost.com/issues/january-25-2026/a-battle-with-my-blood/
https://ascopost.com/issues/january-25-2026/a-battle-with-my-blood/
🆕 The January 2026 issue of The ASCO Post features: highlights from ASH 2025, SABCS 2025, and GI 2026; and an essay written by Tatiana Schlossberg about her battle with AML reprinted following her death.
Don’t miss this issue 👉 https://ascopost.com/issues/january-25-2026/
Don’t miss this issue 👉 https://ascopost.com/issues/january-25-2026/
January 23, 2026 at 6:15 PM
🆕 The January 2026 issue of The ASCO Post features: highlights from ASH 2025, SABCS 2025, and GI 2026; and an essay written by Tatiana Schlossberg about her battle with AML reprinted following her death.
Don’t miss this issue 👉 https://ascopost.com/issues/january-25-2026/
Don’t miss this issue 👉 https://ascopost.com/issues/january-25-2026/
📢 The FDA has issued a draft guidance for the use of minimal residual disease and complete response as endpoints in multiple myeloma clinical trials to support accelerated approval.
https://ow.ly/Q5bc50Y1n9K
https://ow.ly/Q5bc50Y1n9K
January 22, 2026 at 9:45 PM
📢 The FDA has issued a draft guidance for the use of minimal residual disease and complete response as endpoints in multiple myeloma clinical trials to support accelerated approval.
https://ow.ly/Q5bc50Y1n9K
https://ow.ly/Q5bc50Y1n9K
⚖️💊 FDA & EMA set global principles for good, responsible AI use in drug development.
New guidance outlines 🔟 best practices to ensure AI tools support safe, ethical, and effective drug innovation.
Read the full list of principles here 👉 https://ow.ly/C9Ka50Y0BC0
New guidance outlines 🔟 best practices to ensure AI tools support safe, ethical, and effective drug innovation.
Read the full list of principles here 👉 https://ow.ly/C9Ka50Y0BC0
January 21, 2026 at 6:45 PM
⚖️💊 FDA & EMA set global principles for good, responsible AI use in drug development.
New guidance outlines 🔟 best practices to ensure AI tools support safe, ethical, and effective drug innovation.
Read the full list of principles here 👉 https://ow.ly/C9Ka50Y0BC0
New guidance outlines 🔟 best practices to ensure AI tools support safe, ethical, and effective drug innovation.
Read the full list of principles here 👉 https://ow.ly/C9Ka50Y0BC0
📊American Cancer Society’s Cancer Stats, 2026:
⬆️ 5-yr survival rate for all cancers = 70%
⬆️ Significantly increased 5-yr survival rates: multiple myeloma, liver cancer, metastatic melanoma, regional lung cancer
⬇️ Mortality rate dropped by 34% through 2023
https://ow.ly/bukz50Y0gX9
⬆️ 5-yr survival rate for all cancers = 70%
⬆️ Significantly increased 5-yr survival rates: multiple myeloma, liver cancer, metastatic melanoma, regional lung cancer
⬇️ Mortality rate dropped by 34% through 2023
https://ow.ly/bukz50Y0gX9
January 20, 2026 at 7:30 PM
📊American Cancer Society’s Cancer Stats, 2026:
⬆️ 5-yr survival rate for all cancers = 70%
⬆️ Significantly increased 5-yr survival rates: multiple myeloma, liver cancer, metastatic melanoma, regional lung cancer
⬇️ Mortality rate dropped by 34% through 2023
https://ow.ly/bukz50Y0gX9
⬆️ 5-yr survival rate for all cancers = 70%
⬆️ Significantly increased 5-yr survival rates: multiple myeloma, liver cancer, metastatic melanoma, regional lung cancer
⬇️ Mortality rate dropped by 34% through 2023
https://ow.ly/bukz50Y0gX9
🥫 Study highlights possible links between select food preservatives and cancer risk:
• Potassium sorbate, potassium nitrate, total acetates → ⬆️ overall & breast cancer risk
• Sodium nitrite → ⬆️ prostate cancer risk
🔹Hasenböhler et al |
https://ow.ly/oJlT50XWc7r
• Potassium sorbate, potassium nitrate, total acetates → ⬆️ overall & breast cancer risk
• Sodium nitrite → ⬆️ prostate cancer risk
🔹Hasenböhler et al |
https://ow.ly/oJlT50XWc7r
January 13, 2026 at 6:15 PM
🥫 Study highlights possible links between select food preservatives and cancer risk:
• Potassium sorbate, potassium nitrate, total acetates → ⬆️ overall & breast cancer risk
• Sodium nitrite → ⬆️ prostate cancer risk
🔹Hasenböhler et al |
https://ow.ly/oJlT50XWc7r
• Potassium sorbate, potassium nitrate, total acetates → ⬆️ overall & breast cancer risk
• Sodium nitrite → ⬆️ prostate cancer risk
🔹Hasenböhler et al |
https://ow.ly/oJlT50XWc7r
📊 Final data from phase III AGO-OVAR 2.29:
No significant OS or PFS benefit with atezolizumab + bevacizumab + nonplatinum chemo in recurrent ovarian cancer, though a paclitaxel subgroup showed a favorable OS signal.
🔸 Philipp Harter, MD
🔗 https://ow.ly/PYjn50XVIWN
No significant OS or PFS benefit with atezolizumab + bevacizumab + nonplatinum chemo in recurrent ovarian cancer, though a paclitaxel subgroup showed a favorable OS signal.
🔸 Philipp Harter, MD
🔗 https://ow.ly/PYjn50XVIWN
January 12, 2026 at 9:45 PM
📊 Final data from phase III AGO-OVAR 2.29:
No significant OS or PFS benefit with atezolizumab + bevacizumab + nonplatinum chemo in recurrent ovarian cancer, though a paclitaxel subgroup showed a favorable OS signal.
🔸 Philipp Harter, MD
🔗 https://ow.ly/PYjn50XVIWN
No significant OS or PFS benefit with atezolizumab + bevacizumab + nonplatinum chemo in recurrent ovarian cancer, though a paclitaxel subgroup showed a favorable OS signal.
🔸 Philipp Harter, MD
🔗 https://ow.ly/PYjn50XVIWN
🔬COMMIT trial shows triplet therapy (FOLFOX + bevacizumab + atezolizumab) significantly improved PFS vs atezolizumab alone in 1L dMMR/MSI-H mCRC (HR = 0.43)
• 12-mo PFS: 67% vs 35%
Caio Max Sao Pedro Rocha Lima, MD, MS
🔗 https://ow.ly/Mpgl50XT5Yw
• 12-mo PFS: 67% vs 35%
Caio Max Sao Pedro Rocha Lima, MD, MS
🔗 https://ow.ly/Mpgl50XT5Yw
January 8, 2026 at 10:15 PM
🔬COMMIT trial shows triplet therapy (FOLFOX + bevacizumab + atezolizumab) significantly improved PFS vs atezolizumab alone in 1L dMMR/MSI-H mCRC (HR = 0.43)
• 12-mo PFS: 67% vs 35%
Caio Max Sao Pedro Rocha Lima, MD, MS
🔗 https://ow.ly/Mpgl50XT5Yw
• 12-mo PFS: 67% vs 35%
Caio Max Sao Pedro Rocha Lima, MD, MS
🔗 https://ow.ly/Mpgl50XT5Yw
🍔A study found higher fast-food spending by block in Alabama was linked to more cases of early-onset colorectal cancer, while higher fruit & vegetable spending had a strong protective effect.🥦
🔹 Blake Buchalter, MPH, PhD
🔗 https://ow.ly/urH650XT29I
🔹 Blake Buchalter, MPH, PhD
🔗 https://ow.ly/urH650XT29I
January 7, 2026 at 8:45 PM
🍔A study found higher fast-food spending by block in Alabama was linked to more cases of early-onset colorectal cancer, while higher fruit & vegetable spending had a strong protective effect.🥦
🔹 Blake Buchalter, MPH, PhD
🔗 https://ow.ly/urH650XT29I
🔹 Blake Buchalter, MPH, PhD
🔗 https://ow.ly/urH650XT29I
🔮 The path forward isn’t AI instead of clinicians—but human+AI collaboration, according to Michael Sobolev, PhD et al.
🔹 Public trust, including for AI’s role in #cancer detection (currently ~15% of survey respondents), grows with experience.
🔗 https://ow.ly/EOYs50XS1A7
🔹 Public trust, including for AI’s role in #cancer detection (currently ~15% of survey respondents), grows with experience.
🔗 https://ow.ly/EOYs50XS1A7
January 6, 2026 at 11:15 PM
🔮 The path forward isn’t AI instead of clinicians—but human+AI collaboration, according to Michael Sobolev, PhD et al.
🔹 Public trust, including for AI’s role in #cancer detection (currently ~15% of survey respondents), grows with experience.
🔗 https://ow.ly/EOYs50XS1A7
🔹 Public trust, including for AI’s role in #cancer detection (currently ~15% of survey respondents), grows with experience.
🔗 https://ow.ly/EOYs50XS1A7
🔬Postoperative ctDNA testing may help personalize adjuvant therapy in patients with colon cancer—identifying those most likely to benefit from NSAIDs like celecoxib added to chemotherapy.
👨⚕️ George Q. Zhang, MD, MPH
🔗 https://ow.ly/XuPs50XS1p3
👨⚕️ George Q. Zhang, MD, MPH
🔗 https://ow.ly/XuPs50XS1p3
January 6, 2026 at 7:25 PM
🔬Postoperative ctDNA testing may help personalize adjuvant therapy in patients with colon cancer—identifying those most likely to benefit from NSAIDs like celecoxib added to chemotherapy.
👨⚕️ George Q. Zhang, MD, MPH
🔗 https://ow.ly/XuPs50XS1p3
👨⚕️ George Q. Zhang, MD, MPH
🔗 https://ow.ly/XuPs50XS1p3
📊Phase III inMIND trial: Adding tafasitamab to lenalidomide + rituximab significantly improved PFS in patients with relapsed/refractory Follicular Lymphoma (22.4 vs 13.9 months; HR = 0.43).
🔺Laurie H. Sehn, MD
🔗 https://ow.ly/PYBQ50XS1kF
🔺Laurie H. Sehn, MD
🔗 https://ow.ly/PYBQ50XS1kF
January 6, 2026 at 3:01 PM
📊Phase III inMIND trial: Adding tafasitamab to lenalidomide + rituximab significantly improved PFS in patients with relapsed/refractory Follicular Lymphoma (22.4 vs 13.9 months; HR = 0.43).
🔺Laurie H. Sehn, MD
🔗 https://ow.ly/PYBQ50XS1kF
🔺Laurie H. Sehn, MD
🔗 https://ow.ly/PYBQ50XS1kF
New meta-analysis shows that GLP-1 receptor agonists likely have little or no effect on obesity-related #cancer risk.
Longer-term, cancer-specific studies still needed.
🔸Ko et al
🔗 https://ascopost.com/news/december-2025/study-explores-association-of-glp-1-ras-with-risk-of-obesity-related-cancers/
Longer-term, cancer-specific studies still needed.
🔸Ko et al
🔗 https://ascopost.com/news/december-2025/study-explores-association-of-glp-1-ras-with-risk-of-obesity-related-cancers/
January 5, 2026 at 5:20 PM
New meta-analysis shows that GLP-1 receptor agonists likely have little or no effect on obesity-related #cancer risk.
Longer-term, cancer-specific studies still needed.
🔸Ko et al
🔗 https://ascopost.com/news/december-2025/study-explores-association-of-glp-1-ras-with-risk-of-obesity-related-cancers/
Longer-term, cancer-specific studies still needed.
🔸Ko et al
🔗 https://ascopost.com/news/december-2025/study-explores-association-of-glp-1-ras-with-risk-of-obesity-related-cancers/
🩸 Potential new standard of care in newly diagnosed Multiple Myeloma
ADVANCE trial from ASCO25: Adding daratumumab to KRd significantly improved MRD negativity vs KRd alone—without added toxicity in selected patients.
👨⚕️ C. Ola Landgren, MD, PhD
🔗 https://ow.ly/Cx2L50XNJ7S
ADVANCE trial from ASCO25: Adding daratumumab to KRd significantly improved MRD negativity vs KRd alone—without added toxicity in selected patients.
👨⚕️ C. Ola Landgren, MD, PhD
🔗 https://ow.ly/Cx2L50XNJ7S
January 2, 2026 at 9:00 PM
🩸 Potential new standard of care in newly diagnosed Multiple Myeloma
ADVANCE trial from ASCO25: Adding daratumumab to KRd significantly improved MRD negativity vs KRd alone—without added toxicity in selected patients.
👨⚕️ C. Ola Landgren, MD, PhD
🔗 https://ow.ly/Cx2L50XNJ7S
ADVANCE trial from ASCO25: Adding daratumumab to KRd significantly improved MRD negativity vs KRd alone—without added toxicity in selected patients.
👨⚕️ C. Ola Landgren, MD, PhD
🔗 https://ow.ly/Cx2L50XNJ7S
Happy New Year from The ASCO Post!
January 1, 2026 at 3:01 PM
Happy New Year from The ASCO Post!
🔬 TAP Highlight of 2025: Is this the end of cancer research as we know it?
A proposed 15% cap on NIH indirect (F&A) costs threatens labs, clinical trials, and decades of progress in #CancerResearch—jeopardizing patients and innovation nationwide.
🔗 https://ow.ly/IGA850XNJ41
A proposed 15% cap on NIH indirect (F&A) costs threatens labs, clinical trials, and decades of progress in #CancerResearch—jeopardizing patients and innovation nationwide.
🔗 https://ow.ly/IGA850XNJ41
December 31, 2025 at 7:00 PM
🔬 TAP Highlight of 2025: Is this the end of cancer research as we know it?
A proposed 15% cap on NIH indirect (F&A) costs threatens labs, clinical trials, and decades of progress in #CancerResearch—jeopardizing patients and innovation nationwide.
🔗 https://ow.ly/IGA850XNJ41
A proposed 15% cap on NIH indirect (F&A) costs threatens labs, clinical trials, and decades of progress in #CancerResearch—jeopardizing patients and innovation nationwide.
🔗 https://ow.ly/IGA850XNJ41
#YearInReview: In matched-related donor stem cell transplantation, cyclophosphamide + calcineurin inhibition significantly improved GVHD- & relapse-free survival vs standard therapy—without added toxicity. From #EHA25
🔸 David Curtis, MBBS, PhD
🔗 https://ow.ly/ZfQ450XNJ1R
🔸 David Curtis, MBBS, PhD
🔗 https://ow.ly/ZfQ450XNJ1R
December 30, 2025 at 2:01 PM
#YearInReview: In matched-related donor stem cell transplantation, cyclophosphamide + calcineurin inhibition significantly improved GVHD- & relapse-free survival vs standard therapy—without added toxicity. From #EHA25
🔸 David Curtis, MBBS, PhD
🔗 https://ow.ly/ZfQ450XNJ1R
🔸 David Curtis, MBBS, PhD
🔗 https://ow.ly/ZfQ450XNJ1R
TAP Highlight of 2025 - Update in early HER2+ Breast Cancer:
• Adjuvant: T-DXd beat T-DM1 in high-risk residual disease (HR = 0.47)
• Neoadjuvant: T-DXd→THP improved pCR (67.3% vs 56.3%)
• Signals for fewer CNS events (DB05)
🔗 https://ow.ly/3BCO50XNIRO
• Adjuvant: T-DXd beat T-DM1 in high-risk residual disease (HR = 0.47)
• Neoadjuvant: T-DXd→THP improved pCR (67.3% vs 56.3%)
• Signals for fewer CNS events (DB05)
🔗 https://ow.ly/3BCO50XNIRO
December 29, 2025 at 4:45 PM
TAP Highlight of 2025 - Update in early HER2+ Breast Cancer:
• Adjuvant: T-DXd beat T-DM1 in high-risk residual disease (HR = 0.47)
• Neoadjuvant: T-DXd→THP improved pCR (67.3% vs 56.3%)
• Signals for fewer CNS events (DB05)
🔗 https://ow.ly/3BCO50XNIRO
• Adjuvant: T-DXd beat T-DM1 in high-risk residual disease (HR = 0.47)
• Neoadjuvant: T-DXd→THP improved pCR (67.3% vs 56.3%)
• Signals for fewer CNS events (DB05)
🔗 https://ow.ly/3BCO50XNIRO
🚨 ICYMI: NCCN early 2025 updates impacted practice across:
• 🫙 Bladder: periop/sandwich IO + chemo; HER2-targeted options
• 🫁 NSCLC/SCLC: more periop + consolidation IO; tarlatamab added
• 🧬 mCRC: expanded IO + BRAF-targeted combos
• 🩸 Myeloma: quadruplets gaining ground
🔗 https://ow.ly/1j7j50XNIzM
• 🫙 Bladder: periop/sandwich IO + chemo; HER2-targeted options
• 🫁 NSCLC/SCLC: more periop + consolidation IO; tarlatamab added
• 🧬 mCRC: expanded IO + BRAF-targeted combos
• 🩸 Myeloma: quadruplets gaining ground
🔗 https://ow.ly/1j7j50XNIzM
December 26, 2025 at 7:00 PM
🚨 ICYMI: NCCN early 2025 updates impacted practice across:
• 🫙 Bladder: periop/sandwich IO + chemo; HER2-targeted options
• 🫁 NSCLC/SCLC: more periop + consolidation IO; tarlatamab added
• 🧬 mCRC: expanded IO + BRAF-targeted combos
• 🩸 Myeloma: quadruplets gaining ground
🔗 https://ow.ly/1j7j50XNIzM
• 🫙 Bladder: periop/sandwich IO + chemo; HER2-targeted options
• 🫁 NSCLC/SCLC: more periop + consolidation IO; tarlatamab added
• 🧬 mCRC: expanded IO + BRAF-targeted combos
• 🩸 Myeloma: quadruplets gaining ground
🔗 https://ow.ly/1j7j50XNIzM
Wishing you a wonderful holiday season!
December 25, 2025 at 5:01 PM
Wishing you a wonderful holiday season!
👉 Major takeaways from Treatment Advances in Malignant Hematology from NCCNhem25:
• Immunotherapy-first strategies expanding
• MRD driving treatment intensity
• Biomarkers guiding frontline choices
• Outpatient management of cellular therapies
🔗 https://ow.ly/bU3350XNIyw
• Immunotherapy-first strategies expanding
• MRD driving treatment intensity
• Biomarkers guiding frontline choices
• Outpatient management of cellular therapies
🔗 https://ow.ly/bU3350XNIyw
December 24, 2025 at 4:02 PM
👉 Major takeaways from Treatment Advances in Malignant Hematology from NCCNhem25:
• Immunotherapy-first strategies expanding
• MRD driving treatment intensity
• Biomarkers guiding frontline choices
• Outpatient management of cellular therapies
🔗 https://ow.ly/bU3350XNIyw
• Immunotherapy-first strategies expanding
• MRD driving treatment intensity
• Biomarkers guiding frontline choices
• Outpatient management of cellular therapies
🔗 https://ow.ly/bU3350XNIyw
Deb Schrag, MD, MPH, has been chosen as the American Society of Clinical Oncology President for 2027–2028
The new Board of Directors and Nominating Committee Members have also been chosen. They will start their terms after the 2026 ASCO Annual Meeting.
🔗https://ow.ly/8Ve050XNLay
The new Board of Directors and Nominating Committee Members have also been chosen. They will start their terms after the 2026 ASCO Annual Meeting.
🔗https://ow.ly/8Ve050XNLay
Deb Schrag, MD, MPH, FASCO, Elected 2027–2028 ASCO President
Dr. Schrag, a gastrointestinal medical oncologist, is the George J. Bosl Chair of the Department of Medicine at Memorial Sloan Kettering Cancer Center and Professor of Medicine at Weill Cornell Medica...
ow.ly
December 23, 2025 at 8:45 PM
Deb Schrag, MD, MPH, has been chosen as the American Society of Clinical Oncology President for 2027–2028
The new Board of Directors and Nominating Committee Members have also been chosen. They will start their terms after the 2026 ASCO Annual Meeting.
🔗https://ow.ly/8Ve050XNLay
The new Board of Directors and Nominating Committee Members have also been chosen. They will start their terms after the 2026 ASCO Annual Meeting.
🔗https://ow.ly/8Ve050XNLay